- Atara Biotherapeutics ( NASDAQ: ATRA ) on Wednesday said it had amended the terms of its existing collaboration agreement with French pharmaceutical company Pierre Fabre for the commercialization of its tabelecleucel therapy for the treatment of Epstein-Barr virus-positive cancers.
- ATRA said it would now get an additional $30M milestone payment upon European Commission approval and subsequent filing of the marketing approval transfer to Pierre Fabre.
- In exchange, Pierre Fabre would get reduced tabelecleucel royalties and supply price-mark up.
- Tiered royalties on sales remain at a significant double-digit rate following the amendment, ATRA said in a statement .
- The company added that the anticipated European Commission approval for tabelecleucel was on track for Q4.
- Atara Biotherapeutics ( ATRA ) stock earlier closed more than 15% higher .
For further details see:
Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre